Brokerages Set OptimizeRx Corp. (NASDAQ:OPRX) Target Price at $21.00

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have received a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $21.00.

OPRX has been the topic of a number of recent analyst reports. Stephens dropped their price target on shares of OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Monday, November 17th. Citizens Jmp lifted their target price on shares of OptimizeRx from $23.00 to $24.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Wall Street Zen raised shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a research report on Sunday, December 14th. Zacks Research downgraded OptimizeRx from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 15th. Finally, UBS Group set a $23.00 price objective on OptimizeRx in a research report on Friday, October 10th.

OptimizeRx Price Performance

Shares of NASDAQ:OPRX opened at $12.15 on Tuesday. OptimizeRx has a fifty-two week low of $3.99 and a fifty-two week high of $22.25. The business has a 50-day moving average of $13.83 and a two-hundred day moving average of $15.83. The stock has a market capitalization of $226.49 million, a P/E ratio of 31.50 and a beta of 1.09. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.05 and a quick ratio of 3.05.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.17. OptimizeRx had a return on equity of 6.37% and a net margin of 0.03%.The business had revenue of $26.07 million for the quarter, compared to analyst estimates of $23.83 million. On average, equities research analysts predict that OptimizeRx will post -0.33 EPS for the current fiscal year.

Institutional Investors Weigh In On OptimizeRx

Several hedge funds and other institutional investors have recently modified their holdings of OPRX. Los Angeles Capital Management LLC bought a new position in shares of OptimizeRx during the 2nd quarter worth approximately $349,000. Rhumbline Advisers grew its holdings in shares of OptimizeRx by 10.5% in the 1st quarter. Rhumbline Advisers now owns 27,785 shares of the company’s stock worth $241,000 after purchasing an additional 2,636 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of OptimizeRx in the 2nd quarter worth about $418,000. P.A.W. Capital Corp acquired a new stake in shares of OptimizeRx during the 2nd quarter worth about $675,000. Finally, Calamos Advisors LLC increased its position in shares of OptimizeRx by 38.2% during the 2nd quarter. Calamos Advisors LLC now owns 46,173 shares of the company’s stock worth $623,000 after purchasing an additional 12,774 shares in the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.